Maxim Group reiterated their hold rating on shares of ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) in a research report report published on Thursday.

ImmunoCellular Therapeutics (NASDAQ IMUC) traded down 6.8923% during trading on Thursday, reaching $0.3026. 1,204,993 shares of the company’s stock traded hands. The firm’s market capitalization is $4.79 million. The firm has a 50 day moving average of $0.56 and a 200 day moving average of $1.65. ImmunoCellular Therapeutics has a 1-year low of $0.25 and a 1-year high of $6.32.

TRADEMARK VIOLATION NOTICE: “ImmunoCellular Therapeutics Ltd (IMUC) Given Hold Rating at Maxim Group” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Stock Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related stocks with our FREE daily email newsletter.